- Hinge Health says its digital physical therapy service, combining app-based exercises with virtual clinician support, reduces human care team hours by about 95% compared with traditional physical therapy. Operating margin was 29% in the most recent quarter excluding some items, against a target of at least 35%.
- Revenue is expected to grow roughly 46% this year to about $858 million, with the company targeting ongoing growth of 20% or more annually thereafter. Market capitalisation stands near $8 billion, around nine times expected revenue, with the stock up more than 200% since its May 2025 listing and outpacing the Russell 2000 Health Care Index.
- Chief executive Daniel Perez said the company expects further acquisitions, particularly in hardware, arguing that too many digital health companies shy away from it. Hinge already sells Enso, a small wearable block intended to relieve pain through electrical pulses.
- The company recently agreed to buy Cylinder Health, focused on digestive health, for $105 million in cash, and has started a migraine care programme as it expands beyond musculoskeletal conditions. Perez said Hinge is fielding two or three inquiries from digital health companies looking to sell themselves.
What Happened?
The San Francisco-based company plans to combine acquisitions with internal research and development to find new growth avenues, according to Perez speaking to Bloomberg News.
Why It Matters?
The 95% reduction in human care hours is the thesis, and it is the clearest listed example of what AI and automation do to a regulated professional service. This is not software assisting clinicians, it is care delivered almost entirely without them, and the 29% operating margin in physical therapy exists because the labour cost has been removed rather than reduced. Apollo has warned about agents disrupting banking, and legal technology firms are pressuring billable-hour work, but those arguments are mostly prospective. Here the same dynamic appears with audited financials and a market capitalisation attached, which makes it the most concrete evidence available of how far this can go in a licensed field. Investors trying to size the AI labour-substitution theme should study this income statement rather than the forecasts. The hardware strategy sits awkwardly beside the margin target and deserves scrutiny. Devices carry inventory, manufacturing, warranty and regulatory costs, and they structurally dilute software economics, so expanding into hardware while targeting an increase from 29% to 35% operating margin requires the software side to carry considerably more weight. Perez is explicit that this is contrarian, and contrarian can be right, but the margin arithmetic is the thing to watch. The acquisition posture tells you about the sector rather than the company. Receiving inbound approaches from digital health firms wanting to sell, while buying Cylinder for $105 million in cash, indicates private valuations have fallen far enough that a public company with a tripled share price can consolidate cheaply. Using an expensive currency to buy distressed assets is a sound playbook and it also means the sector outside the listed winners is struggling. On valuation, roughly nine times revenue is supported by 46% growth, but the company guides to 20% or more thereafter, which is less than half the current rate. Anyone buying at this multiple is underwriting both the deceleration and the margin expansion.
What Next?
Margin progression from 29% toward the 35% target is the number that matters, particularly as hardware becomes a larger part of the mix. Watch which companies Hinge acquires from the two or three approaches Perez describes, since the prices paid will show how depressed private digital health valuations have become. Revenue growth decelerating from 46% toward the 20% guided range is the expected path, and how smoothly that happens will determine whether the multiple holds. The migraine programme and the Cylinder digestive health acquisition are the tests of whether the model transfers beyond musculoskeletal care, which is the question underlying the entire growth case.
Affected Tickers and Coins: HNGE, TDOC, HIMS
Source: Bloomberg
